In contrast, other cells have robust NRF1 maturation that is detected in the absence of BTZ treatment, suggesting that some MM may engage the DDI2-NRF1 pathways constitutively, either to respond to a very high demand in proteasome activity or as part of developed mechanisms of resistance. The gene discussed is DDI2; the disease is Miyoshi myopathy.